Wellnex Secures AUD 4.6M in Orders, Launches Softgels in UAE
Wellnex Life has secured a significant opening order from global partner Haleon for its Liquid Paracetamol and Ibuprofen softgel products in the UAE, marking the fourth national market in Haleon's distribution network. This milestone supports Wellnex's revenue forecasts for 2025 and underscores its strategic focus on innovative healthcare products.
- Opening UAE order for Liquid Paracetamol and Ibuprofen softgels
- Expansion to fourth national market with Haleon partnership
- Confirmed purchase orders of approximately AUD 4.6 million since July 2025
- Total contract manufacturing orders expected to reach AUD 5.4 million in FY25
- Strategic validation of Wellnex’s global supply partnerships and product innovation
Wellnex Life Broadens Global Footprint
Wellnex Life Limited, a consumer healthcare company listed on both the ASX and AIM, has announced a key development in its international expansion strategy. Through its subsidiary BSPS Aust Pty Ltd, Wellnex has received an opening order from its global partner Haleon plc for its TGA-registered Liquid Paracetamol and Ibuprofen softgel products destined for the United Arab Emirates (UAE). This marks the fourth national market in Haleon's global distribution network supported by Wellnex, following Australia, New Zealand, and the United Kingdom.
Revenue Growth and Market Validation
The new UAE agreement is expected to generate additional revenue within the current financial year, reinforcing Wellnex’s market forecasts. While the specific terms of supply remain confidential, the deal expands Wellnex’s product line with Haleon beyond the already launched Liquid Paracetamol softgel. This extension not only broadens the company’s geographic reach but also validates its strategic focus on developing innovative consumer healthcare products and forging strong global supply partnerships.
Robust Order Book and Contract Manufacturing Momentum
Since 1 July 2025, Wellnex has secured confirmed purchase orders from various contract manufacturing customers totaling approximately AUD 4.6 million, all expected to be invoiced by the end of December 2025. These orders add to around AUD 0.8 million already invoiced earlier in the financial year, bringing total contract manufacturing revenues to an estimated AUD 5.4 million. This steady inflow of orders highlights Wellnex’s growing manufacturing capabilities and its ability to meet demand across multiple markets.
Strategic Acquisitions and Future Outlook
Wellnex Life’s recent acquisition of the Australian topical pain relief brand Pain Away in December 2023 complements its expanding product portfolio and accelerates growth potential. CEO Zack Bozinovski expressed enthusiasm about the partnership with Haleon and the international launch of their innovative softgel products, emphasizing the company’s commitment to partnering with global leaders to unlock significant distribution opportunities worldwide.
As Wellnex continues to build on its licensing and manufacturing strengths, the company is well-positioned to capitalize on the growing consumer healthcare market both domestically and internationally.
Bottom Line?
Wellnex’s expanding global partnerships and robust order pipeline set the stage for sustained growth, but investors will watch closely for further market entries and revenue details.
Questions in the middle?
- What are the specific financial terms and margins of the new UAE supply agreement?
- Will Wellnex pursue additional product launches or new markets with Haleon or other partners soon?
- How will the Pain Away acquisition integrate operationally and financially into Wellnex’s broader strategy?
